AZALEA-TIMI 71 is a phase 2b, multicenter, randomized, active-controlled study to evaluate the safety and tolerability of two blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban in patients with atrial fibrillation.
MAIN RESULTS PRESENTATIONS
AZALEA-TIMI 71-A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared with Open-Label Rivaroxaban in Patients with Atrial Fibrillation (Christian Ruff, AHA 2023)
AZALEA on ClinicalTrials.gov
CONTACT US about AZALEA